Local Research, Global Results
Below are several examples of current research studies at Froedtert & The Medical College of Wisconsin. For more information on our clinical trials, call 414-805-3666 or 800-272-3666.
Clinical Research in EpilepsyIf you have partial seizures, you may be eligible for one of two trials using Lyrica® (pregabalin). Lyrica is FDA approved as an add-on therapy for adults already taking one or more anti-epileptic drugs (AEDs).
Lyrica® as Monotherapy Trial
“Lyrica has been proven effective as an add-on therapy for people with partial onset seizures,” said Jo Bergholte, MS, a program manager at The Medical College of Wisconsin. “When a patient is taking multiple epilepsy drugs, there can be complications, so the goal is to be on one medication, if possible. This study will determine if Lyrica works well alone, without other AEDs.”
Froedtert & The Medical College are among 50 sites across the country participating in this clinical trial. Ekrem Kutluay, MD, Medical College of Wisconsin neurologist, is the principal investigator. In the study, patients gradually stop taking their current AEDs and gradually increase the dosage of Lyrica. Then, they take only Lyrica for 12 weeks. Patients may choose to extend the study, which requires receiving Lyrica for six more months.
Lyrica® and Vision Trial
This study involves examining the eyes of patients taking Lyrica for possible effects on vision. Bernd Remmler, MD, Medical College of Wisconsin chief of Adult Neurology and a neuro-opthalmologist, is the principal investigator for the study. During the study, patients remain on their current AEDs, and Lyrica is added to the AEDs over 15 weeks. Throughout the study, patients have periodic comprehensive vision evaluations with a neuro-ophthalmologist at the Froedtert & The Medical College Eye Institute. Patients who complete the study may receive a pharmacy card good for a six month supply of up to three AEDs.
Bone and Soft Tissue Cancer Clinical TrialRadiation Oncologist DianWang, MD, PhD, is leading a national trial as part of the Radiation Therapy Oncology Group, a National Cancer Institute-sponsored cooperative group. The goal is to enroll 102 adult patients with soft tissue sarcomas of the arm or leg. Soft tissue sarcoma is a cancer of the soft tissues, which connect, support or surround other tissues. Examples include muscles, tendons, fat and blood vessels.
Recent advances in delivering radiation treatment have focused on the ability to precisely locate the tumor using image-guided radiation therapy (IGRT). IGRT delivers targeted radiation to the tumor with less radiation to surrounding normal tissue. This study aims to find out what effect IGRT has on patients and their tumors by comparing the long term side effects and rates of disease recurrence with patients who were previously treated with radiation that covered a wider treatment area.
For a summary of the trial, visit clinicaltrials.gov (RTOG No. 0630).
Source: Froedtert Today
Date: December 2008